Immunic director awarded 25,370 stock options

IMMUNIC, INC. director Jon Congleton received a grant of stock options covering 25,370 shares of common stock at an exercise price of $14.80 per share.

Rhea-AI Filing Summary

IMMUNIC, INC. director Jon Congleton received a grant of stock options covering 25,370 shares of common stock at an exercise price of $14.80 per share. The option vests in monthly installments over one year from the grant date and expires on July 5, 2036. Following this grant, Congleton holds 25,370 options directly, with no accompanying share purchases or sales reported.

Insider Trade Summary

Grant/Award: 25,370 shares

Grant/Award 1 txn

Insider Congleton Jon

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option	25,370	$0.00	$0.00

Holdings After Transaction: Stock Option — 25,370 contracts (Direct)

Footnotes (1)

1. F1. The option vests in monthly increments over a period of one year from the grant date.

Key Figures

Stock options granted: 25,370 options Exercise price: $14.80 per share Underlying shares: 25,370 common shares +2 more

5 metrics

Stock options granted 25,370 options Grant to director Jon Congleton on July 5, 2026

Exercise price $14.80 per share Strike price for Congleton’s stock option award

Underlying shares 25,370 common shares Shares subject to the option grant

Expiration date July 5, 2036 Option term for Congleton’s grant

Total options after grant 25,370 options Direct holdings following this transaction

Key Terms

Stock Option, grant/award acquisition, Common Stock, vests in monthly increments

4 terms

Stock Option financial

"The security reported is titled "Stock Option" linked to common stock."

A stock option is a contract that gives you the right to buy or sell a company's stock at a specific price within a certain time frame. People use them to potentially make money if the stock's price moves favorably or to protect against losses. It's like holding a coupon that can be used to buy or sell stock at a set price later on.

grant/award acquisition financial

"The transaction_action field notes a "grant/award acquisition"."

Common Stock financial

"The underlying security title for the option is "Common Stock"."

Common stock represents ownership shares in a company, giving investors a stake in its success and a say in important decisions through voting rights. It is the most common type of stock traded on markets and can provide income through dividends, as well as potential for value growth. For investors, holding common stock means sharing in the company’s profits and risks.

vests in monthly increments financial

"The option vests in monthly increments over a period of one year."

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did IMMUNIC (IMUX) report for Jon Congleton?

IMMUNIC reported that director Jon Congleton received a grant of 25,370 stock options. These options relate to common stock and represent equity-based compensation rather than an open-market share purchase or sale by the director.

What is the exercise price of Jon Congleton’s IMMUNIC (IMUX) stock options?

The granted stock options have an exercise price of $14.80 per share. This is the price at which Congleton may buy IMMUNIC common shares if he chooses to exercise the options in the future.

How do Jon Congleton’s IMMUNIC (IMUX) stock options vest?

The option award vests in monthly increments over one year from the grant date. This means a portion of the 25,370 options becomes exercisable each month during the first year after the grant.

When do Jon Congleton’s IMMUNIC (IMUX) stock options expire?

The stock options granted to Jon Congleton expire on July 5, 2036. After this expiration date, any unexercised options will lapse and can no longer be used to purchase IMMUNIC common stock.

Did Jon Congleton buy or sell IMMUNIC (IMUX) shares in this Form 4?

No open-market share purchases or sales were reported. The Form 4 only shows a compensation-related acquisition of 25,370 stock options, classified as a grant or award rather than a market trade.

How many IMMUNIC (IMUX) options does Jon Congleton hold after this grant?

After this transaction, Jon Congleton holds 25,370 stock options directly. This total reflects the new grant reported and does not indicate any prior option or share holdings in this specific filing.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 07/07/2026 - 04:05 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Congleton Jon

(Last) (First) (Middle)

1200 AVENUE OF THE AMERICAS, SUITE 200

(Street)

NEW YORK NEW YORK 10036

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
IMMUNIC, INC. [ IMUX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
07/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option	$14.8	07/05/2026		A		25,370		(1)	07/05/2036	Common Stock	25,370	$0.00	25,370	D

Explanation of Responses:

1. The option vests in monthly increments over a period of one year from the grant date.

	/s/ Jon Congleton	07/07/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)